Outpatient myeloablative allo-SCT: A comprehensive approach yields decreased hospital utilization and low TRM

Bone Marrow Transplantation

Volumn 45, Issue 3, 2010, Pages 468-475

  Solomon, S R ^a,b   Matthews, R H ^a   Barreras, A M ^a   Bashey, A ^a,b   Manion, K L ^a   McNatt, K ^a   Speckhart, D ^a   Connaghan, D G ^a,b   Morris, L E ^a,b   Holland, H K ^a,b  

^a NORTHSIDE HOSPITAL   (United States)

^b Blood and Marrow Transplant Group of Georgia   (United States)

Author keywords

Allogeneic; Hematopoietic SCT; Myeloablative; Outpatient

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MESNA; METHOTREXATE; TACROLIMUS;

ADULT; ARTICLE; CONTINUOUS INFUSION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; INFUSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; AMBULATORY CARE; FEMALE; GRAFT SURVIVAL; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMANS; INFECTION; KAPLAN-MEIERS ESTIMATE; LENGTH OF STAY; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 77949424430     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.234     Document Type: Article

References (23)

1. Cornelissen JJ, Lowenberg B. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2005, 151-155.
2. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006; 106: 2657-2663.
3. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
4. Svahn DM, Ringdén O, Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation 2005; 36: 511-516.
5. Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997; 15: 1608-1616.
6. Bennett C, Waters T, Stinson T, Almagor O, Pavletic Z, Tarantolo S et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 555-560.
7. Gilbert C, Meisenberg B, Vredenburgh J, Ross M, Hussein A, Perfect J et al. Sequential prophylactic oral and empiric oncedaily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12: 1005-1011.
8. Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Dukelow K et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21: 25-31.
9. Fernández-Avilés F, Carreras E, Urbano-Ispizua A, Rovira M, Martínez C, Gaya A et al. Case-control comparison of athome to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol 2006; 24: 4855-4861.
10. Leger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, Bredeson C et al. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol 2006; 85: 723-729.
11. Schulmeister L, Quiett K, Mayer K. Quality of life, quality of care, and patient satisfaction: perceptions of patients undergoing outpatient autologous stem cell transplantation. Oncol Nurs Forum 2005; 32: 57-67.
12. Rovira M. Outpatient management of autologous haematopoietic cell transplantation: the Barcelona experience. Presse Med 2004; 33: 479-481.
13. Chandrasekar PH, Abraham OC, Klein J, Alangaden G, Chalasani G, Cassells L et al. Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer. Clin Infect Dis 2001; 32: 546-551.
14. Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998; 21: 927-932.
15. Glü ck S, des Rochers C, Cano C, Dorreen M, Germond C, Gill K et al. High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach. Bone Marrow Transplant 1997; 20: 431-434.
16. Subirà M, Sureda A, Ancin I, Martino R, Alté s A, Brunet S et al. Allogeneic stem cell transplantation with reducedintensity conditioning is potentially feasible as an outpatient procedure. Bone Marrow Transplant 2003; 32: 869-872.
17. Maris M, Storb R. Outpatient allografting in hematologic malignancies and nonmalignant disorders-applying lessons learned in the canine model to humans. Cancer Treat Res 2002; 110: 149-175.
18. Ruiz-Argü elles GJ, Gómez-Almaguer D, Ruiz-Argü elles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am J Hematol 2001; 66: 241-244.
19. Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999; 17: 2811-2818.
20. Matthews RH, Emami M, Connaghan DG, Holland HK, Morris LE. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 397-400.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
22. Millman Research Report: 2008 US organ tissue transplant cost estimate and discussion. 7 April 2008.
23. Russell JA, Chaudhry A, Booth K, Brown C, Woodman RC, Valentine K et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 2000; 6: 109-114.